Microbiotica Limited

The microbiome represents a paradigm shift that affects every aspect of biomedicine: our gut bacteria control health, disease and drug response throughout the body, and can themselves be a novel type of medicine. The microbiome therefore has the potential to be a major new therapeutic modality. Microbiotica was founded by Dr Trevor Lawley, Prof Gordon Dougan FRS and Dr Mike Romanos in December 2016 to exploit fundamental advances made at the Sanger Institute to address barriers to the translation of the microbiome. A central premise has been that a more rigorous and comprehensive analysis and understanding of the role of the gut bacteria in patients is required to drive the development of Live Bacterial Therapeutics and microbiome-based biomarkers of disease and drug response.